PharmacyCodes



Mepivacaina [INN-Spanish] en es it fr

Mepivacaina [INN-Spanish] Brand names, Mepivacaina [INN-Spanish] Analogs

Mepivacaina [INN-Spanish] Brand Names Mixture

  • No information avaliable

Mepivacaina [INN-Spanish] Chemical_Formula

C4H11N5

Mepivacaina [INN-Spanish] RX_link

http://www.rxlist.com/cgi/generic4/glumetza.htm

Mepivacaina [INN-Spanish] fda sheet

Mepivacaina_[INN-Spanish] FDA

Mepivacaina [INN-Spanish] msds (material safety sheet)

Mepivacaina_[INN-Spanish] MSDS

Mepivacaina [INN-Spanish] Synthesis Reference

No information avaliable

Mepivacaina [INN-Spanish] Molecular Weight

129.164 g/mol

Mepivacaina [INN-Spanish] Melting Point

223-226 oC

Mepivacaina [INN-Spanish] H2O Solubility

Freely soluble as HCl salt

Mepivacaina [INN-Spanish] State

Solid

Mepivacaina [INN-Spanish] LogP

-0.267

Mepivacaina [INN-Spanish] Dosage Forms

Extended release tablet (500 mg or 1000 mg)

Mepivacaina [INN-Spanish] Indication

For use as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes.

Mepivacaina [INN-Spanish] Pharmacology

Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.

Mepivacaina [INN-Spanish] Absorption

Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. Food delays absorption.

Mepivacaina [INN-Spanish] side effects and Toxicity

Acute oral toxicity (LD50): 350 mg/kg [Rabbit]. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen.

Mepivacaina [INN-Spanish] Patient Information

Mepivacaina [INN-Spanish] Organisms Affected

Humans and other mammals